NDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
TORADOL (ketorolac tromethamine) by Roche is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. Approved for pain, postoperative, cataract, low back pain and 1 more indications. First approved in 1991.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORADOL (ketorolac tromethamine) is an oral NSAID tablet approved in 1991 for acute pain management, particularly postoperative pain, low back pain, and pain associated with cataract surgery and osteoarthritis. It works by inhibiting prostaglandin synthetase, with peak analgesic effects occurring within 2-3 hours and duration varying by dose.
LOE Approaching
As an LOE-approaching product nearing generic competition, TORADOL teams face declining market share and potential right-sizing, requiring strategic focus on differentiated formulations or indication expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on TORADOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.